Interpace Biosciences Announces Record Third Quarter 2023 Fi

 ●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial...

Related Keywords

United States , Chris Mccarthy , Interpace Bioscience , Tom Burnell , Interpace Biosciences , Company Medicare , Exchange Commission , Company Line Of Credit , Globenewswire Inc , Interpace Biosciences Inc , Novitas Solutions Inc , Securities Exchange , Comerica Bank , Company Annual Report On Form , Net Revenue , Chief Financial , Terminal Payment , Oak Capital Partners , Third Quarter , Nine Months Ended , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Annual Report , Current Reports , Quarterly Reports , Balance Sheet Data , Cash Flow Data , Nine Months , Markets ,